加载中
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
前收盘价
US$2.90
+US$0.06 · +2.11%
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
60
合理估值
情绪
42
多空交织
风险
67
高风险
动量
69
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
日内区间
当前US$2.90
52周区间
当前US$2.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4052万 USD | 3231.4万 USD | 7812.3万 USD | 1971.2万 USD | 2554.4万 USD |
| 销货成本 | — | 1.99亿 USD | 606.4万 USD | 633.7万 USD | 505.3万 USD |
| 毛利 | 4052万 USD | −1.67亿 USD | 7205.9万 USD | 1337.5万 USD | 2049.1万 USD |
| 研究与开发 | 8995.3万 USD | 1.99亿 USD | 1.78亿 USD | 1.75亿 USD | 1.43亿 USD |
| 销售、一般及管理费用 | 4990.3万 USD | 7198.7万 USD | 6965.3万 USD | 7070.4万 USD | 7618.3万 USD |
| 营业费用 | 1.4亿 USD | 8421.9万 USD | 2.41亿 USD | 2.39亿 USD | 2.14亿 USD |
| 利息收入 | 831万 USD | 1406.2万 USD | 1756.6万 USD | 551.8万 USD | 60.7万 USD |
| 利息支出 | 617.1万 USD | — | — | — | — |
| 折旧和摊销 | 527.7万 USD | 580.9万 USD | 606.4万 USD | 633.7万 USD | 505.3万 USD |
| 营业利润 | −9933.6万 USD | −2.51亿 USD | −1.69亿 USD | −2.26亿 USD | −1.93亿 USD |
| 净利润 | −1.6亿 USD | −2.37亿 USD | −1.53亿 USD | −2.2亿 USD | −1.93亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 72.41%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1496.38万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1217.39万0.12%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1149.28万0.01%787.4亿 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO366.55万0.03%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF350.52万0.00%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB304.82万0.03%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA198.62万0.01%218.24亿 USD0.03%US$32.79+0.40%
Vanguard Russell 2000 ETFVTWO176.26万0.01%180亿 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
